[1] JANUS N, THARIAT J, BOULANGER H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients[J]. Ann Oncol,2010,21(7):1395-1403. doi:  10.1093/annonc/mdp598
[2] HERBST R S, KHURI F R. Mode of action of docetaxel - a basis for combination with novel anticancer agents[J]. Cancer Treat Rev,2003,29(5):407-415. doi:  10.1016/S0305-7372(03)00097-5
[3] 江泽飞, 李健斌. 乳腺癌诊疗指南和临床实践历程[J]. 中华外科杂志, 2020, 58(2):85-90. doi:  10.3760/cma.j.issn.0529-5815.2020.02.002
[4]

CHEW S C, SINGH O, CHEN X G, et al. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients[J]. Cancer Chemother Pharmacol,2011,67(6):1471-1478. doi:  10.1007/s00280-011-1625-9
[5]

ASHBEE H R, BARNES R A, JOHNSON E M, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology[J]. J Antimicrob Chemother,2014,69(5):1162-1176. doi:  10.1093/jac/dkt508
[6]

ALEXANDRE J, REY E, GIRRE V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study[J]. Ann Oncol,2007,18(1):168-172. doi:  10.1093/annonc/mdl321
[7]

BAKER SD, LI J, TEN TIJE AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia[J]. Clin Pharmacol Ther,2005,77(1):43-53. doi:  10.1016/j.clpt.2004.09.005
[8]

SUN N, SHEN B, ZHU J L, et al. Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study[J]. J Transl Med,2020,18(1):226. doi:  10.1186/s12967-020-02394-w
[9]

JANUS N, LAUNAY-VACHER V, DERAY G, et al. Gestion des chimiothérapies chez les patients hémodialysés[J]. Bull Cancer,2012,99(3):371-380. doi:  10.1684/bdc.2011.1483
[10]

GARLAND L L, HIDALGO M, MENDELSON D S, et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors[J]. Clin Cancer Res, 2006, 12(14 Pt 1): 4274-4282.
[11]

KUO J C, CRAFT P S. Administration of chemotherapy in patients on dialysis[J]. Anticancer Drugs,2015,26(7):779-784. doi:  10.1097/CAD.0000000000000243
[12]

LABAKI C, RAWADI E, CHEBEL R, et al. Anti-neoplastic agents for patients on peritoneal dialysis: a systematic review[J]. Crit Rev Oncol Hematol,2020,150:102947. doi:  10.1016/j.critrevonc.2020.102947
[13]

JANUS N, LAUNAY-VACHER V. Anticancer drugs in end-stage kidney disease patients[J]. Semin Dial,2015,28(4):413-416. doi:  10.1111/sdi.12371
[14] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8):609-680. doi:  10.19401/j.cnki.1007-3639.2019.08.009
[15]

BAILLE P, BRUNO R, SCHELLENS J H, et al. Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance[J]. Clin Cancer Res,1997,3(9):1535-1538.
[16]

ENGELS F K, LOOS W J, VAN DER BOL J M, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study[J]. Clin Cancer Res,2011,17(2):353-362. doi:  10.1158/1078-0432.CCR-10-1636
[17]

ANDRIGUETTI N B, RAYMUNDO S, ANTUNES M V, et al. Pharmacogenetic and pharmacokinetic dose individualization of the taxane chemotherapeutic drugs paclitaxel and docetaxel[J]. Curr Med Chem,2017,24(33):3559-3582.
[18]

MA Y X, LIN Q G, YANG Y P, et al. Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients[J]. Ann Transl Med,2020,8(5):236. doi:  10.21037/atm.2020.01.76
[19] 蒋侃, 黄诚, 林根, 等. 检测多西他赛血药浓度指导晚期非小细胞肺癌患者的个体化治疗[J]. 临床肿瘤学杂志, 2018, 23(7):610-614. doi:  10.3969/j.issn.1009-0460.2018.07.007
[20]

RIGO-BONNIN R, COBO-SACRISTÁN S, GONZALO-DIEGO N, et al. Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry[J]. J Pharm Biomed Anal,2016,117:140-149. doi:  10.1016/j.jpba.2015.08.025
[21]

YANG Q L, ZHENG J Z, CHEN W Y, et al. Association between preadmission metformin use and outcomes in intensive care unit patients with Sepsis and type 2 diabetes: a cohort study[J]. Front Med (Lausanne),2021,8:640785.
[22]

KENMOTSU H, TANIGAWARA Y. Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose[J]. Cancer Sci,2015,106(5):497-504. doi:  10.1111/cas.12647
[23]

JOERGER M. Treatment regimens of classical and newer taxanes[J]. Cancer Chemother Pharmacol,2016,77(2):221-233. doi:  10.1007/s00280-015-2893-6
[24]

ALKEN S, KELLY C M. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer[J]. Cancer Manag Res,2013,5:357-365.
[25]

CLARKE S J, RIVORY L P. Clinical pharmacokinetics of docetaxel[J]. Clin Pharmacokinet,1999,36(2):99-114. doi:  10.2165/00003088-199936020-00002